Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 16,851 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Symptom Clusters Clear all

Conditions: Chronic Graft Versus Host Disease
Interventions: Abatacept; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Cystic Fibrosis, Gastrointestinal Diseases, Cholestasis
Interventions: ursodiol; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 4 Months and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: MDS
Interventions: Lenalidomide and azacitidine combination; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections
Interventions: HIV self-test, Counseling; Diagnostic Test · Behavioral
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 811 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Septic Shock
Interventions: Simvastatin, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Enfuvirtide, Efavirenz, lamivudine, and tenofovir; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 70 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Myelodysplastic Syndromes
Interventions: cenersen, Dexamethasone; Drug
Lead sponsor: Eleos, Inc.; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Developmental Delay Disorders, Chromosome Deletion, Mental Retardation, Sleep Disorders, Circadian Rhythm, Self Injurious Behavior
Interventions: dTR Melatonin (NIH CC PDS), Phototherapy (Bright Light), Melatonin CR; Drug · Device
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 3 Years to 45 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cascade Testing, Lynch Syndrome, Decision Making, Colorectal Cancer, Uterine Cancer, Cancer Prevention
Interventions: Information Letter and Booklet, Information Letter; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Severe Sepsis
Interventions: Severe sepsis early warning best practice alert, Standard care; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 1,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Post Prandial Distress Syndrome
Interventions: Placebo, 20 mg ATI 7505, 40 mg ATI 7505, 80 mg ATI 7505; Drug
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 44
States / cities: Chino, California • Fresno, California • Los Angeles, California + 37 more

Conditions: Perimenopause, PMDD
Interventions: transcutaneous auricular neurostimulation (tAN); Device
Lead sponsor: Texas Christian University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Acute Coronary Syndrome
Interventions: Ticagrelor; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Intestinal Disease, Inflammatory Bowel Diseases, Crohn Disease, Ulcer, Celiac Disease
Interventions: SV-3 Capsule Endoscopy; Device
Lead sponsor: Capso Vision, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Saratoga, California

Conditions: MELAS Syndrome, Mitochondrial Diseases
Interventions: Medium-Chain Triglycerides; Dietary Supplement
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Not listed
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Endocrine Neoplasia Syndromes
Interventions: Questionnaires; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: Conventional Pressure Controlled SIMV, Mid-frequency Ventilation; Procedure · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Hour to 7 Days
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Craniofrontonasal Syndrome, CFNS
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: Not listed
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes, HIV Infections, Insulin Resistance
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 72 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Kaposi's Sarcoma
Interventions: VEGF inhibitor PTC299, gene expression analysis, polymerase chain reaction, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy; Drug · Genetic · Other + 1 more
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years to 120 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 8
States / cities: La Jolla, California • Los Angeles, California • Honolulu, Hawaii + 4 more

Conditions: Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Interventions: UX007, Placebo; Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 1 Year to 100 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 8
States / cities: Aurora, Colorado • Miami, Florida • Orlando, Florida + 4 more

Conditions: HTLV-I Infection, Spinal Cord Disease, Tropical Spastic Paraparesis
Interventions: Recombinant human interferon beta-1a; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dry Eye Syndromes
Interventions: Lubricant Eye Drops (Optive™), Lubricating Eye Drops (blink® Tears); Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chevy Chase, Maryland

Conditions: Hypertension, FXTAS
Interventions: HRV and respiratory coherence biofeedback; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 50 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)

Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease

A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes

eTest: Real-time, Remote Monitoring System for Home-based HIV Testing Among High-risk Men Who Have Sex With Men

Statin Therapy in the Treatment of Sepsis

A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy

A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)

Treatment Strategies for Children With Smith-Magenis Syndrome

Initial Testing of a Behavioral Intervention About Genetic Services for Families at Risk of Lynch Syndrome

Study of an Electronic Health Record-embedded Severe Sepsis Early Warning Alert

A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome

Transcutaneous Auricular Neurostimulation (tAN) for Premenstrual Dysphoric Disorder (PMDD) and Perimenopause

The ACS Ethnicity Platelet Function Study

Validation of CapsoVision CapsoCam® SV-3 Capsule Endoscopy System

Ketones & Mitochondrial Heteroplasmy

Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2

Feasibility of Mid-frequency Ventilation in Newborns With RDS: Randomized Crossover Pilot Trial

Genetic Analysis of Craniofrontonasal Syndrome

The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism

PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma

Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)

Efficacy and Acceptability of Two Lubricant Eye Drops

Diaphragmatic Breathing and Heart Rate Variability Training for Improving Hypertension in Fragile X Associated Tremor/Ataxia